Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Eschweiler

833 clinical trials in Eschweiler, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Eschweiler at a glance
833
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

833 trials in Eschweiler

Open in trial search

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

Breast cancer

Recruiting

Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BioNTech SE

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Eschweiler

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer and HER2-positive breast cancer treatments, evaluating new therapeutic combinations and personalized approaches.

  • Early-stage breast cancer therapies
  • Hormone receptor-positive treatments
  • Neoadjuvant chemotherapy studies

Research includes novel combinations of immunotherapy and targeted treatments to improve patient outcomes.

02 Blood Cancer Studies

Comprehensive research into various blood cancers, including multiple myeloma, lymphoma, and leukemia, testing innovative treatment approaches.

  • Advanced therapy combinations
  • Maintenance treatment strategies
  • Novel drug applications

Trials focus on improving survival rates and developing more effective treatment protocols.

03 Lung Cancer Innovation

Groundbreaking research in non-small cell lung cancer treatment, exploring immunotherapy combinations and targeted therapies.

  • Immunotherapy development
  • Adjuvant treatment studies
  • Disease-free survival assessment

Studies aim to enhance treatment efficacy through innovative drug combinations and personalized approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.